(IN BRIEF) QIAGEN has received U.S. FDA clearance for the QIAstat-Dx BCID GPF Plus AMR Panel, its first QIAstat-Dx bloodstream infection panel cleared for the U.S. market. The panel detects 20 gram-positive bacterial and fungal pathogen targets, a broad pan … Read the full press release
Posted in Business, Germany, Government, Healthcare, Netherlands, Pharma & Biotech, Science, Technology
Tagged 100 countries, 200 placements, 5, AMR, antibiotic use, antimicrobial resistance markers, antimicrobial stewardship, bloodstream infection diagnostics, bloodstream infections, clinical decision making, data analysis, FDA, FDA Clears QIAGEN QIAstat-Dx Panel for Rapid Bloodstream Infection Testing, FDA review, Frankfurt Prime Standard, fungal pathogens, gastrointestinal panel, genetic resistance markers, Germantown, gram-positive bacteria, infection prevention, infectious disease testing, laboratory diagnostics, Maryland, meningitis encephalitis panel, Molecular Diagnostics, multiplex PCR, Netherlands, Nitin Sood, one-hour results, pan gram-negative target, pathogen detection, positive blood cultures, QGEN, QIA, QIAGEN, QIAGEN Launches First FDA-Cleared QIAstat-Dx BCID Panel for U.S. Laboratories, QIAstat-Dx, QIAstat-Dx BCID GN Plus AMR Panel, QIAstat-Dx BCID GPF Plus AMR Panel, QIAstat-Dx BCID GPF Plus AMR Panel Detects Pathogens and Resistance Markers in About One Hour, QIAstat-Dx Gastrointestinal Panel 2, QIAstat-Dx GI Panel 2 Mini B, QIAstat-Dx GI Panel 2 Mini B&V, QIAstat-Dx Meningitis/Encephalitis Panel, QIAstat-Dx Respiratory Panel Mini, QIAstat-Dx Respiratory Panel Plus, rapid testing, respiratory panel, sample preparation, SEPSIS, syndromic testing, U.S. Food and Drug Administration, U.S. laboratories, Venlo
(IN BRIEF) QIAGEN has highlighted its molecular testing portfolio as U.S. health authorities investigate a growing Cyclospora outbreak. More than 1,600 confirmed cases of cyclosporiasis have been reported in the United States since May 2026, with another 7,000 potential cases … Read the full press release
Posted in Business, Food & Beverage, Healthcare, Netherlands, Pharma & Biotech, Science, Technology
Tagged clinical diagnostics, Cyclospora cayetanensis, cyclosporiasis, digital PCR, emerging disease threats, FDA-cleared test, foodborne disease outbreak, foodborne parasite, gastrointestinal illness, gastrointestinal pathogens, infectious disease detection, Molecular Diagnostics, molecular testing, next-generation sequencing, NGS, Nitin Sood, outbreak investigation, prolonged diarrhoea, public health laboratories, PulseNet, QIAcuity, QIAGEN, QIAGEN Molecular Diagnostics Portfolio Supports Response to Rising Cyclosporiasis Cases, QIAGEN N.V., QIAseq FX DNA Library Prep Kit, QIAstat-Dx Gastrointestinal Panel 2, QIAstat-Dx Gastrointestinal Panel 2 Detects Cyclospora as U.S. Cases Continue to Increase, Research Use Only, Rising U.S. Cyclospora Cases Underscore Need for Rapid Molecular Testing QIAGEN Says, Sample to Insight, shotgun sequencing, syndromic testing
(IN BRIEF) Evotec SE has created a new Executive Vice President role that combines Global Communications and Investor Relations as part of a broader effort to strengthen strategic clarity and stakeholder engagement. Dr. Sarah Fakih has been appointed to lead … Read the full press release
Posted in Business, Germany, Healthcare, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged capital markets strategy, Christian Wojczewski, Corporate Communications, CureVac, Evotec SE, executive appointment, Global Communications, Hamburg Germany, Investor Relations, life sciences leadership, MorphoSys, QIAGEN, Sarah Fakih, stakeholder engagement, Volker Braun
(IN BRIEF) QIAGEN has received FDA approval for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its syndromic testing offerings for gastrointestinal infections in the U.S. This new panel targets five major bacterial pathogens and complements the previously cleared QIAstat-Dx … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged bacterial pathogens, Campylobacter, clinical needs, diagnostic solutions, diagnostic workflows, FDA clearance, Gastrointestinal Infections, healthcare flexibility, healthcare providers, Infectious Diseases Society of America, laboratories, Nadia Aelbrecht, outpatient use, partnership, QIAGEN, QIAstat-Dx Gastrointestinal Panel 2 Mini B, QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, QIAstat-Dx Rise, QIAstat-Dx system, real-time PCR, Salmonella, Shigella, STEC, syndromic testing, Yersinia enterocolitica
(IN BRIEF) QIAGEN has filed a lawsuit against bioMérieux in the German Unified Patent Court to protect its QuantiFERON technology, specifically its European Patent EP 2 276 883 B2, which covers innovations in QuantiFERON-TB Gold Plus used for TB detection. … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Law, Management, Netherlands, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged bioMérieux, CDC, Düsseldorf, European Patent EP 2 276 883 B2, infectious disease diagnostics, intellectual property, latent tuberculosis, Molecular Diagnostics, patent lawsuit, public health, QIAGEN, QuantiFERON technology, QuantiFERON-TB Gold Plus, SD Biosensor, TB detection, Thierry Bernard, tuberculosis, tuberculosis control, Unified Patent Court, WHO
(IN BRIEF) QIAGEN is investing in a new innovation hub in Esplugues de Llobregat, Barcelona, to enhance its QIAstat-Dx syndromic testing platform. Opening in 2026, the 8,000-square-meter site will house operations across research, manufacturing, and regulatory functions, focusing on advancing … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Spain, Technology
Tagged Barcelona, Innovation Hub, partnership, QIAGEN, QIAstat-Dx Operations, sustainability, Thierry Bernard
(IN BRIEF) QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel has received FDA clearance, enabling faster and more accurate diagnosis of critical CNS infections like meningitis and encephalitis. This panel, the fourth QIAstat-Dx test approved in the U.S. in 2024, uses real-time PCR to … Read the full press release
(IN BRIEF) QIAGEN has announced FDA clearance for its QIAstat-Dx Respiratory Panel Mini, marking the third such approval for the QIAstat-Dx system in 2024. Tailored for outpatient settings, this panel quickly detects five common respiratory pathogens—including influenza strains and SARS-CoV-2—enabling … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged FDA approval, influenza strains, Nadia Aelbrecht, Outpatient Respiratory Diagnostics, QIAGEN, QIAstat-Dx Mini Panel, Rapid Results, safety, SARS-CoV-2
(IN BRIEF) QIAGEN Digital Insights has announced an expanded partnership with Neo4j, aiming to enhance biomedical data analysis for the biopharmaceutical industry. This collaboration will integrate Neo4j’s graph database and machine learning capabilities with QIAGEN’s extensive biomedical knowledge base. By … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged Biomedical Data Analysis, Biopharma Industry, Dominic John, Neo4j, partnership, QIAGEN, Sudhir Hasbe, sustainability, USA
(IN BRIEF) QIAGEN has launched an upgraded version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), tailored for high-throughput next-generation sequencing (NGS) labs. The new release enhances performance metrics like turnaround time and diagnostic yield through … Read the full press release
(IN BRIEF) QIAGEN, a leading provider of molecular diagnostics and life sciences solutions, is significantly expanding its operations in the Middle East region. In early 2024, the company will open its regional headquarters in Riyadh, Saudi Arabia, to strengthen its … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged Middle East, Oman, partnership, QIAGEN, Riyadh HQ, Saudi Ministry of Health, Simona Grandits, sustainability, TB Screening Initiative
(IN BRIEF) QIAGEN is organizing the Global TB Clinical and Educational Summit 2023, running from October 17-19, with the theme “Tackling TB together: From awareness to action.” This summit highlights QIAGEN’s dedication to combat tuberculosis (TB) and address the gap … Read the full press release
(IN BRIEF) QIAGEN has launched the QIAseq Normalizer Kits, a new solution for researchers to efficiently pool different DNA libraries for optimal results in next-generation sequencing (NGS) runs. The kit accelerates the process of normalizing DNA concentrations across libraries, reducing … Read the full press release
(IN BRIEF) QIAGEN has entered into a partnership with global pharmaceutical group, Servier, to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor used to treat acute myeloid leukemia (AML). QIAGEN will develop and validate a real-time … Read the full press release
13 new kits and assays allow for quantification of AAV viral titer and residual host cell DNA in cell and gene therapy Custom assay design provides dPCR users with access to tailored multiplex assays for use beyond biopharma applications Milestone … Read the full press release
Posted in Business, Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged AAV, adeno-associated virus, biopharma, Cell and Gene Therapy, CGT, Dana Cipriano, digital PCR, DNA, dPCR, dPCR Assays, good manufacturing practice, imaging, QIAcuity, QIAGEN, qPCR, Residual DNA Quantification Kits, thermocycling, Thomas Schweins
13 nouveaux kits et tests permettent de quantifier le titre viral d’AAV et l’ADN résiduel de la cellule hôte en thérapie cellulaire et génique La conception de tests personnalisés permet aux utilisateurs de dPCR d’accéder à des tests multiplex personnalisés … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech, Science, Technology
Tagged AAV, adeno-associated virus, biopharma, Cell and Gene Therapy, CGT, Dana Cipriano, digital PCR, DNA, dPCR, dPCR Assays, good manufacturing practice, imaging, QIAcuity, QIAGEN, qPCR, Residual DNA Quantification Kits, thermocycling, Thomas Schweins
13 neue Kits und Tests ermöglichen die Quantifizierung von AAV-Titern und restlicher Wirtszell-DNA in der Zell- und Gentherapie Custom Assay Design Service bietet Nutzern von dPCR Zugang zu maßgeschneiderten Multiplex-Assays über den Einsatz in Biopharma-Anwendungen hinaus Meilenstein mit mehr als … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Technology
Tagged AAV, adeno-associated virus, Adeno-assoziiertes Virus, Bildgebung, biopharma, Cell and Gene Therapy, CGT, Dana Cipriano, digital PCR, digitale PCR, DNA, dPCR, dPCR Assays, dPCR-Assays, good manufacturing practice, gute Herstellungspraxis, imaging, QIAcuity, QIAGEN, qPCR, Residual DNA Quantification Kits, Rest-DNA-Quantifizierungskits, thermocycling, Thomas Schweins, Zell- und Gentherapie
HILDEN, Deutschland, GERMANTOWN, Maryland (USA), und SHANGHAI, China, 7-Feb-2022 — /EuropaWire/ — QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA), ein deutscher Anbieter von Sample-to-Insights-Lösungen, die es Kunden ermöglichen, Einblicke in die Bausteine des Lebens – DNA, RNA und Proteine … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged China National Medical Products Administration, Chinese Academy of Medical Sciences, Dr. Gao Lei, IGR, Interferon-Gamma Release Assays, Jean-Pascal Viola, NMPA, QFT-Plus, QIAGEN, QIAGEN NV, QIAreach QFT, QIAreach QuantiFERON-TB, QuantiFERON Tuberkulose, QuantiFERON-TB Gold Plus, TB-Bakterien, TB-Diagnose, TB-Infektionen, TB-Tests, TST, Tuberkulin-Hauttest, UNITAID, Weltgesundheitsorganisation, WHO
(COMMUNIQUÉ DE PRESSE) HILDEN, Germany / GERMANTOWN, MD, United Staes / SHANGHAI, 7-Feb-2022 — /EuropaWire/ — QIAGEN NV (NYSE : QGEN ; Frankfurt Prime Standard : QIA), une société allemande fournisseur de solutions Sample to Insights qui permettent aux clients de débloquer des informations sur … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science, Technology
Tagged Académie chinoise des sciences médicales, bactérie de la tuberculose, dépistage de la tuberculose, diagnostic de la tuberculose, Dr. Gao Lei, IGR, infections tuberculeuses, Jean-Pascal Viola, NMPA, OMS, Organisation mondiale de la santé, QFT-Plus, QIAGEN, QIAGEN NV, QIAreach QFT, QIAreach QuantiFERON-TB, QuantiFERON tuberculosis, QuantiFERON-TB® Gold Plus, test cutané à la tuberculine, TST, UNITAID
(PRESS RELEASE) HILDEN, Germany / GERMANTOWN, MD, United Staes / SHANGHAI, 7-Feb-2022 — /EuropaWire/ — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a German provider of Sample to Insights solutions that enable customers to unlock insights from the building … Read the full press release
Posted in Germany, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged China National Medical Products Administration, Chinese Academy of Medical Sciences, Dr. Gao Lei, IGR, Interferon-Gamma Release Assays, Jean-Pascal Viola, NMPA, QFT-Plus, QIAGEN, QIAGEN N.V., QIAreach QFT, QIAreach QuantiFERON-TB, QuantiFERON tuberculosis, QuantiFERON-TB Gold Plus, TB bacteria, TB diagnosis, TB infections, TB testing, TST, Tuberculin Skin Test, UNITAID, WHO, World Health Organization
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?